CONVERT‑HB1: a Phase 2 Trial About Prostate Directed Treatment After Systemic Treatment in mHSPC
CONVERT‑HB1 trial addresses a long‑standing uncertainty in metastatic hormone‑sensitive prostate cancer: whether aggressively treating the primary prostate tumor adds meaningful benefit for patients who already have high‑volume metastatic disease and are receiving modern intensified systemic therapy. For years, data from studies like STAMPEDE and HORRAD suggested that local treatment to the prostate might help men […]